Patent · US Active

Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment

US9879320B2 · kind B2 · utility

0Cited by
1References
26Claims
0Family size

Inventors

Key dates

Filing dateFeb 9, 2012
Grant dateJan 30, 2018
Priority date
Expiry dateFeb 9, 2032

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.